menu
    • menu

    Company profile for Larimar Therapeutics

    NEW Drugs in Dev: 2
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Larimar Therapeutics, based in the Philadelphia area, is committed to discovering and developing treatments for complex rare diseases, with an initial focus on Friedreich’s ataxia. Its proprietary protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that currently have ineffective or no treatments available.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Larimar TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Three Bala Plaza East Suite 506 Bala Cynwyd, PA 19004
    Telephone
    Telephone
    844-511-9056
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://larimartx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Larimar Pharma Gets FDA Breakthrough Status For Nomlabofusp
    Larimar Pharma Gets FDA Breakthrough Status For Nomlabofusp

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243356/0/en/Larimar-Therapeutics-Announces-FDA-Breakthrough-Therapy-Designation-for-Nomlabofusp-in-FA-and-Reiterates-Planned-BLA-Submission-in-June-2026.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Larimar Therapeutics To Present At JP Morgan Healthcare Conf
    Larimar Therapeutics To Present At JP Morgan Healthcare Conf

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207678/0/en/Larimar-Therapeutics-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Larimar Therapeutics Reports Third Quarter 2025 Financial Results
    Larimar Therapeutics Reports Third Quarter 2025 Financial Results

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181277/0/en/Larimar-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share
    Larimar Therapeutics Updates Nomlabofusp Program
    Larimar Therapeutics Updates Nomlabofusp Program

    29 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/29/3157570/0/en/Larimar-Therapeutics-Announces-Positive-Data-from-Ongoing-Long-term-Open-Label-Study-and-Updates-to-Nomlabofusp-Program-for-Friedreich-s-Ataxia.html

    GLOBENEWSWIRE
    29 Sep 2025
    Share Share
    Larimar Therapeutics Hosts Conference On Nomlabofusp Program
    Larimar Therapeutics Hosts Conference On Nomlabofusp Program

    28 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/28/3157384/0/en/Larimar-Therapeutics-Announces-Conference-Call-on-the-Nomlabofusp-Program-for-the-Treatment-of-Friedreich-s-Ataxia.html

    GLOBENEWSWIRE
    28 Sep 2025
    Share Share
    Larimar Therapeutics Reports Q2 2025 Financial Results
    Larimar Therapeutics Reports Q2 2025 Financial Results

    14 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/14/3133297/0/en/Larimar-Therapeutics-Reports-Second-Quarter-2025-Financial-Results.html

    GLOBENEWSWIRE
    14 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search